A sensitive method to quantify human cell-free circulating DNA in blood: Relevance to myocardial infarction screening.
Jing RR, Wang HM, Cui M, Fang MK, Qiu XJ, Wu XH, Qi J, Wang YG, Zhang LR, Zhu JH, Ju SQ
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine the effects of blood component, gender, and diagnosis of MI on cf-DNA levels in blood. Blood was separated after collection and then frozen at -80 degrees C until all specimens were obtained. Serum was collected in serum separator tubes (SST).
Summary of Findings
Serum had more cf-DNA than EDTA plasma. There was insignificantly lower cf-DNA in EDTA plasma from males than females (p>0.05), but males had significantly lower levels of cf-DNA in serum than females (mean 154.6 versus 255.8 ng/mL, P<0.05). The levels of cf-DNA were much higher in the plasma of patients with MI than in normal controls (median of 4439.4 and 117.6 ng/mL, respectively). There was no correlation of cf-DNA levels with CK-MB, cTnI, or MYO. In serially collected specimens, cf-DNA peaked before cTnI. The assay was able to accurately quantify cf-DNA at concentrations of 20-400 ng/mL with a coefficient of variance of 13.04, 7.54, and 7.53 for 20 ng/mL, 100 ng/mL and 200 ng/mL, respectively.
Biospecimens
FluidPlasmaFluidSerumFluidBloodPreservation Types
FrozenDiagnoses
NormalCardiovascular DiseasePlatforms
DNABranch DNA assayProteinImmunoassayPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition Myocardial infarctNormalPreaquisition Patient gender FemaleMaleBiospecimen Acquisition Time of biospecimen collection After angioplastyAt admissionBefore angioplastyBiospecimen Aliquots and Components Blood and blood products PlasmaSerumImmunoassay Specific Targeted peptide/protein Creatine kinase-MBMyoglobinTroponin 1